| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see mesalamine) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907) (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...drugbank/halfLife
| |
| http://linked.open...ugbank/indication
| - For the treatment of Crohn's disease and rheumatoid arthritis as a second-line agent. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - The mode of action of Sulfasalazine or its metabolites, 5-aminosalicylic acid (5-ASA) and sulfapyridine (SP), is still under investigation, but may be related to the anti-inflammatory and/or immunomodulatory properties that have been observed in animal and <i>in vitro</i> models, to its affinity for connective tissue, and/or to the relatively high concentration it reaches in serous fluids, the liver and intestinal walls, as demonstrated in autoradiographic studies in animals. In ulcerative colitis, clinical studies utilizing rectal administration of Sulfasalazine, SP and 5-ASA have indicated that the major therapeutic action may reside in the 5-ASA moiety. The relative contribution of the parent drug and the major metabolites in rheumatoid arthritis is unknown. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...outeOfElimination
| - The majority of 5-ASA stays within the colonic lumen and is excreted as 5-ASA and acetyl-5-ASA with the feces. (en)
|
| http://linked.open.../drugbank/synonym
| - Sulfasalazine (en)
- Azopyrin (en)
- Azulfidine (en)
- Salazosulfapyridine (en)
- Salicylazosulfapyridine (en)
- Sulfasalazin (en)
- 5-(P-(2-Pyridylsulfamyl)phenylazo)salicylic acid (en)
- Salazosulfapiridina (en)
- Salazosulfapyridinum (en)
- Sulfasalazina (en)
- Sulfasalazinum (en)
- 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene (en)
- 5-((P-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid (en)
- 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid (en)
- 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid (en)
- 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid (en)
|
| http://linked.open...umeOfDistribution
| |
| http://linked.open.../drug/hasAHFSCode
| |
| http://linked.open...k/foodInteraction
| - May take Vitamin D. (en)
- Take with food. (en)
- Take with a full glass of water No iron, zinc or fluoride within 2 hours of taking this medication. (en)
|
| foaf:page
| |
| http://linked.open...ugbank/IUPAC-Name
| |
| http://linked.open...gy/drugbank/InChI
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...noisotopic-Weight
| |
| http://linked.open...y/drugbank/SMILES
| |
| http://linked.open.../Water-Solubility
| |
| http://linked.open...ogy/drugbank/logP
| |
| http://linked.open...ogy/drugbank/logS
| |
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...nd-Acceptor-Count
| |
| http://linked.open...-Bond-Donor-Count
| |
| http://linked.open...drugbank/InChIKey
| |
| http://linked.open...urface-Area--PSA-
| |
| http://linked.open...nk/Polarizability
| |
| http://linked.open...bank/Refractivity
| |
| http://linked.open...atable-Bond-Count
| |
| http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)